Welcome to our dedicated page for STEMTECH CORPORATION SEC filings (Ticker: STEK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Stemtech Corporation (STEK) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As a Nevada holding company trading on the OTCQB market, Stemtech submits periodic and current reports that describe its financial condition, operations, and risk factors related to its stemceutical™ and wellness business model.
For a company focused on stem cell nutrition, nutraceuticals, oral care, skin care, and pet health products, key filings include annual reports on Form 10‑K and quarterly reports on Form 10‑Q. These documents typically present audited or reviewed financial statements, management’s discussion and analysis, and narrative descriptions of Stemtech’s direct sales distribution model, Independent Business Partners (IBPs), international joint ventures, and licensing arrangements. Investors can use these filings to understand how product lines such as the RCM System, OraStem® Toothpaste, Cellect One® Shield: HOCL, Cellect One® Rapid Renew Stem Cell Peptide Night Cream, and StemPets™ fit into the company’s overall operations and strategy.
Stemtech also files specialized forms when reporting timing or other disclosure matters. For example, the company submitted a Form 12b‑25 (NT 10‑Q) to notify the SEC of a delayed quarterly report due to delays in preparing quarterly financial statements, while indicating that the report would be filed within the permitted extension period. Such notifications help readers track the status of required filings and reporting timetables.
On Stock Titan, these SEC filings are updated as they are posted to the EDGAR system. Users can review the full text of forms like 10‑K, 10‑Q, 8‑K, and NT 10‑Q, and take advantage of AI‑powered summaries that explain complex sections in simpler terms. This can be especially useful for understanding disclosures on Stemtech’s stemceutical™ products, international ventures, direct sales structure, and other factors that influence the STEK investment profile.
Stemtech Corporation (STEK) reported another loss-making quarter and raised going concern doubts in its Q3 2025 report. For the quarter ended September 30, 2025, net sales were $852,300, down from $1,031,630 a year earlier, as the company shifted away from lower-margin volume toward core markets. Despite lower revenue, cost controls helped reduce operating loss to $339,217 from $716,470, and net loss narrowed to $812,541 from $1,171,405.
For the nine months, sales fell to $2,418,271 from $3,740,000, but net loss improved to $2,567,547 from $3,376,121 as operating expenses declined by about $1.3 million. The balance sheet remains strained: assets were $3,755,801 against current liabilities of $10,301,779, resulting in a stockholders’ deficit of $6,545,978 and a working capital deficit of about $9.2 million.
Management explicitly concluded that substantial doubt about the company’s ability to continue as a going concern is not alleviated, citing recurring losses, negative operating cash flow, dependence on external financing, and defaults under certain Merchant Cash Advance agreements now in litigation. Stemtech is pursuing private equity raises, a proposed convertible debt facility, cost cuts, and international joint ventures to improve liquidity, but these plans are not yet committed or realized.
Stemtech Corporation filed a Form 12b-25 (NT 10-Q) notifying a late filing of its quarterly report for the period ended September 30, 2025. The company cites delays in preparing its quarterly financial statements as the reason.
The notification lists Charles Arnold, CEO, as the signatory and provides a company contact at (954) 715-6000. The notice was signed on November 14, 2025.